Last month Moderna reported the first individualized cancer vaccine to pass a Phase 3. Moderna CEO Stéphane Bancel and a16z's Jorge Conde on what that actually means: The treatment works by sequencing a patient’s tumor and healthy cells, identifying the mutations relevant to their cancer, and encoding up to 34 of them into an mRNA specific to the individual. Rather than simply unleashing the immune system, the goal is to teach it what to recognize and attack. In this conversation, they…